Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Verkazia in pediatric severe vernal keratoconjunctivitis
NCT01751126Phase 3Completed
- Sponsor
- Santen Pharmaceutical
- Start
- Apr 2013
- Primary completion
- Feb 2016
- Modality
- Small Molecules
- Countries
- 11
01
Overview
A Phase 3 trial of cyclosporine ophthalmic solution in Vernal Keratoconjunctivitis (VKC), sponsored by Santen Pharmaceutical. Started Apr 2013; status: completed.
02
Drugs
cyclosporine ophthalmic solution
03
Conditions
Vernal Keratoconjunctivitis (VKC)
Beyond the preview
Go deeper on NCT01751126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01751126.